Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human RPS6KB2 Anticorps:
anti-Rat (Rattus) RPS6KB2 Anticorps:
anti-Mouse (Murine) RPS6KB2 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal RPS6KB2 Primary Antibody pour IP, WB - ABIN151089
Nardella, Lunardi, Fedele, Clohessy, Alimonti, Kozma, Thomas, Loda, Pandolfi: Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. dans Cancer research 2011
Show all 2 Pubmed References
Human Polyclonal RPS6KB2 Primary Antibody pour WB - ABIN392546
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... dans Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 6 Pubmed References
Human Polyclonal RPS6KB2 Primary Antibody pour IF, WB - ABIN948425
Warner, Bridge, Hewitson, Hodgkinson, Heyam, Massa, Haslam, Chatzifrangkeskou, Evans, Plevin, Sharp, Lagos: S6K2-mediated regulation of TRBP as a determinant of miRNA expression in human primary lymphatic endothelial cells. dans Nucleic acids research 2016
Human Polyclonal RPS6KB2 Primary Antibody pour IP - ABIN151088
Liu, Mao, LaFortune, Alonso, Gallick, Fueyo, Yung: Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. dans Cancer research 2007
p54 (Montrer DDX6 Anticorps)-S6K2 interactome is predominant to the nucleus, whereas p70-S6K1 (Montrer RPS6KB1 Anticorps) is predominant to cytosol.
Overexpression of catalytically-active Akt or knockdown of glycogen synthase kinase-3 (GSK3)-beta, a substrate for Akt, had little effect on Mcl-1 downregulation caused by S6K2 deficiency
We propose that the S6K2/TRBP (Montrer TARBP2 Anticorps) node controls miRNA biogenesis in HDLECs and provides a molecular link between the mTOR (Montrer FRAP1 Anticorps) pathway and the miRNA biogenesis machinery.
discovered that ERBB4 (Montrer ERBB4 Anticorps) and S6K2 were the direct targets of miR (Montrer MLXIP Anticorps)-193a-3p and that PIK3R3 and mTOR (Montrer FRAP1 Anticorps) were the direct targets of miR (Montrer MLXIP Anticorps)-193a-5p in non-small-cell lung cancer
Degradation of Tiam1 (Montrer TIAM1 Anticorps) by casein kinase 1 (Montrer CSNK1A1 Anticorps) and the SCFbetaTrCP ubiquitin ligase controls the duration of mTOR (Montrer FRAP1 Anticorps)-S6K (Montrer RPS6KB1 Anticorps) signaling.
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer.
The p85 S6K1 (Montrer RPS6KB1 Anticorps) promotes H2O2-induced cell death via a rapamycin-insensitive mechanism.
S6K2 amplification was frequently observed in gastric cancer and was related to a poor prognosis
S6K1 and S6K2 gene amplification was associated with a worse prognosis.
S6K2 expression dictates tissue-specific requirement for S6K1 (Montrer RPS6KB1 Anticorps) in mediating aberrant mTORC1 signaling and tumorigenesis
S6K2 loss reduces Th17 skewing and increases regulatory T cell differentiation.
the p70S6K (Montrer RPS6KB1 Anticorps) isoforms have unique and redundant functions in mediating fibrogenic processes, including proliferation, migration.
S6K2 regulates hepatic energy homeostasis by repressing PPARalpha (Montrer PPARA Anticorps) activity.
metabolic functions of S6K (Montrer RPS6KB1 Anticorps) in vivo play a key role as a molecular interface connecting dietary lipids to the endogenous control of energy metabolism.
Data show that the absence of ribosomal protein S6 (Montrer RPS6 Anticorps) kinases 1 and 2 (S6K1 (Montrer RPS6KB1 Anticorps) and S6K2) profoundly impairs animal viability but does not seem to affect the proliferative responses of cells derived from the distinct S6K (Montrer RPS6KB1 Anticorps) genotypes.
S6K2 is activated by IL-3 (Montrer IL-3 Anticorps) in the IL-3 (Montrer IL-3 Anticorps)-dependent Ba/F3 cell line and this is mediated by mTOR (Montrer FRAP1 Anticorps) and its upstream activator PI-3K but not by MAPK (Montrer MAPK1 Anticorps) signal pathways.
parallel increase in p70S6K (Montrer RPS6KB1 Anticorps) activation and tau phosphorylation could be demonstrated by treating wild-type N2a cells with Abeta25-35
mGluR (Montrer GRM8 Anticorps)-LTD is associated with PI3K-, mTOR (Montrer FRAP1 Anticorps)-, and ERK (Montrer EPHB2 Anticorps)-dependent alterations in the phosphorylation of S6 and S6K (Montrer RPS6KB1 Anticorps).
This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 nonidentical kinase catalytic domains and phosphorylates the S6 ribosomal protein and eucaryotic translation initiation factor 4B (eIF4B). Phosphorylation of S6 leads to an increase in protein synthesis and cell proliferation.
70 kDa ribosomal protein S6 kinase 2
, S6 kinase-related kinase
, p70 S6 kinase beta
, p70 S6K-beta
, p70 S6KB
, p70 ribosomal S6 kinase beta
, p70-S6K 2
, ribosomal protein S6 kinase beta-2
, serine/threonine-protein kinase 14 beta
, serine/threonine-protein kinase 14B
, ribosomal protein S6 kinase, 70kDa, polypeptide 2
, S6 kinase 2
, ribosomal protein S6 kinase, 70kD, polypeptide 2